Trial Profile
An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ORZORA
- Sponsors AstraZeneca
- 06 Apr 2023 Results (at data cut-off 17 April 2020, n=177) assessing efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer published in the Gynecologic Oncology
- 28 Sep 2022 This trial has been discontinued in Spain (end date; 2021-12-17), according to European Clinical Trials Database record.
- 07 Jun 2022 Results of Overall survival (OS), presented at the 58th Annual Meeting of the American Society of Clinical Oncology